FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-028									
	hurdon									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

37 Estimated average burden hours per response: 0.5

					or	Section	on 30(h)	of the	Ínvestmen	t Con	npany Act	of 1940							
1. Name and Address of Reporting Person* Rawcliffe Adrian					2. Issuer Name and Ticker or Trading Symbol Wave Life Sciences Ltd. [WVE]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
	VE LIFE S	CIENCES LTD.,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 08/10/2017									er (give title			specify	
733 CONCORD AVE.					4. I	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	IDGE M	1A	02138											Fori	Form filed by One Reporting Pers Form filed by More than One Rep Person				
(City)	(5	State)	(Zip)																
		Tab	le I - Nor	n-Deriv	ative	e Se	curitie	s Ac	quired,	Dis	posed o	of, or Be	neficia	lly Own	ed				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution			Code (Secui Benet Owne	icially d Following	Forn (D) o	Ownership rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) (D)	Price	Trans	ported nsaction(s) str. 3 and 4)			(Instr. 4)		
		Т	able II - I						uired, D s, option					y Owne	i				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivativ Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares						
Share Option (right to buy)	\$18.1	08/10/2017			A		9,000		(1)	0	8/10/2022	Ordinary Shares	9,000	\$0.00	9,000	0	D		

Explanation of Responses:

1. The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on August 10, 2018.

Remarks:

/s/ Adrian Rawcliffe

08/17/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.